Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Large Insider Purchases

Institutional-Scale SEC Form 4 Buy Signals

The Signal of $1M+ Conviction

When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.

Filing Date Trade Date Ticker Company Name Reporting Person Relationship Industry Type Price Qty Total, $ Owned After Change, %
2018-10-17 02:41 2018-10-13 REIS N/A MOODYS CORP /DE/ 10% owner Other BUY $23.00 11,570,797 $266,128,331 14,128,253 +452.4%
2018-10-12 23:10 2018-10-10 CTACU GRID DYNAMICS HOLDINGS, INC. Chaserg Technology Sponsor LLC 10% owner Services-Prepackaged Software BUY $10.00 500,000 $5,000,000 500,000 +100.0%
2018-10-13 01:00 2018-10-10 GCP N/A Dalbergia Investments LLC 10% owner Other BUY $25.04 720,675 $18,046,927 5,383,881 +15.5%
2018-10-12 23:05 2018-10-10 NES N/A Gates Capital Management, L.P. 10% owner Other BUY $9.92 377,800 $3,747,587 5,401,079 +7.5%
2018-10-12 01:11 2018-10-09 APPN Appian Corporation Abdiel Capital Management, LLC 10% owner Services-Prepackaged Software BUY $25.67 166,910 $4,285,214 6,521,402 +2.6%
2018-10-11 23:01 2018-10-10 TA N/A PORTNOY ADAM D. Director Other BUY $5.62 1,492,691 $8,381,460 1,492,691 +100.0%
2018-10-12 00:20 2018-10-09 RUN Sunrun Inc. TIGER GLOBAL MANAGEMENT LLC 10% owner Miscellaneous Electrical Machinery, Equipment & Supplies BUY $11.47 231,357 $2,653,942 15,231,357 +1.5%
2018-10-12 00:57 2018-10-09 KOD Kodiak Sciences Inc. BAKER BROS. ADVISORS LP Director, 10% owner Biological Products, (No Diagnostic Substances) BUY $10.00 2,500,000 $25,000,000 8,374,935 +42.6%
2018-10-10 20:42 2018-10-10 OCCI OFS Credit Company, Inc. Cerny Jeffrey A Director, Officer - Director and CFO Other BUY $20.00 77,500 $1,550,000 70,000 +100.0%
2018-10-10 20:39 2018-10-10 OCCI OFS Credit Company, Inc. Orchard First Source Asset Management, LLC Other Other BUY $20.00 70,000 $1,400,000 70,000 +100.0%
2018-10-10 20:41 2018-10-10 OCCI OFS Credit Company, Inc. Rashid Bilal Director, Officer - President, Director and CEO Other BUY $20.00 77,500 $1,550,000 70,000 +100.0%
2018-10-09 23:46 2018-10-05 KALA KALA BIO, Inc. Grunberg Gregory Director Pharmaceutical Preparations BUY $8.25 606,060 $4,999,995 2,877,006 +26.7%
2018-10-09 23:43 2018-10-04 N/A Blue Owl Capital Corp Ostrover Douglas I Director Other BUY $15.30 179,189 $2,741,592 878,112 +25.6%
2018-10-10 01:44 2018-10-05 GCP N/A Dalbergia Investments LLC 10% owner Other BUY $25.79 477,374 $12,311,619 4,663,206 +11.4%
2018-10-09 22:09 2018-10-05 N-A N/A Golub Lawrence E Director, Officer, 10% owner - Chairman Other BUY $15.00 109,760 $1,646,396 1,821,627 +6.4%
2018-10-09 22:11 2018-10-05 N-A N/A Golub David Director, Officer, 10% owner - President and CEO Other BUY $15.00 109,760 $1,646,396 1,821,627 +6.4%
2018-10-09 23:01 2018-10-05 KMPH ZEVRA THERAPEUTICS, INC. Delaware Street Capital Master Fund, L.P. 10% owner Pharmaceutical Preparations BUY $3.00 2,000,000 $6,000,000 4,095,914 +95.4%
2018-10-09 23:20 2018-10-04 MEET N/A Luxor Capital Group, LP 10% owner Other BUY $5.27 247,567 $1,305,545 2,819,233 +9.6%
2018-10-10 00:19 2018-10-09 SYNT N/A Atos S.E. 10% owner Other BUY $41.00 83,804,409 $3,435,980,769 100 +100.0%
2018-10-05 18:10 2018-10-04 N-A N/A STRS OHIO 10% owner Other BUY $15.00 133,333 $2,000,000 1,864,702 +7.7%
2018-10-05 23:34 2018-10-03 KALA KALA BIO, Inc. Shah Rajeev M. Director, 10% owner Pharmaceutical Preparations BUY $8.25 2,424,242 $19,999,997 4,537,478 +114.7%
2018-10-06 01:58 2018-10-03 APPN Appian Corporation Abdiel Capital Management, LLC 10% owner Services-Prepackaged Software BUY $28.39 375,824 $10,671,109 6,354,492 +6.3%
2018-10-05 23:33 2018-10-03 KALA KALA BIO, Inc. RA CAPITAL MANAGEMENT, LLC Director, 10% owner Pharmaceutical Preparations BUY $8.25 2,424,242 $19,999,997 4,537,478 +114.7%
2018-10-06 00:10 2018-10-04 IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC Gold Alan D Director, Officer - Executive Chairman Real Estate BUY $40.00 67,500 $2,700,000 33,750 +100.0%
2018-10-06 01:36 2018-10-05 EPZM N/A MOTT DAVID M Director Other BUY $9.00 416,667 $3,750,003 6,471,018 +6.9%
2018-10-05 01:02 2018-03-30 MVEN Arena Group Holdings Inc. STROME MARK E 10% owner Cable & Other Pay Television Services BUY $2.34 600,505 $1,405,422 4,485,268 +15.5%
2018-10-05 01:15 2018-10-02 GCP N/A Dalbergia Investments LLC 10% owner Other BUY $26.26 101,900 $2,675,894 4,185,832 +2.5%
2018-10-05 00:31 2018-10-02 GTT N/A SPRUCE HOUSE PARTNERSHIP LP 10% owner Other BUY $44.11 387,933 $17,110,057 10,000,000 +4.0%
2018-10-04 00:01 2018-10-01 OCPIX N/A OppenheimerFunds, Inc. 10% owner Other BUY $10.07 496,524 $5,000,000 4,242,277 +13.3%
2018-10-04 00:47 2018-10-01 UROV N/A SVF Investments (UK) Ltd 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 02:18 2018-10-01 UROV N/A Lo Andrew 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 00:18 2018-10-01 ARVN Arvinas Inc. Loven Jakob Director Pharmaceutical Preparations BUY $16.00 312,500 $5,000,000 312,500 +100.0%
2018-10-04 00:58 2018-10-01 UROV N/A Dexxon Holdings Ltd. 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-03 23:48 2018-10-01 UROV N/A Roivant Sciences Ltd. 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 00:22 2018-10-01 ARVN Arvinas Inc. Ratcliffe Liam Director Pharmaceutical Preparations BUY $16.00 1,000,000 $16,000,000 375,000 +100.0%
2018-10-03 20:52 2018-10-01 OCPIX N/A TC Group Cayman Investment Holdings, L.P. 10% owner Other BUY $10.07 496,524 $5,000,000 4,245,276 +13.2%
2018-10-03 23:36 2018-10-01 ARVN Arvinas Inc. RA CAPITAL MANAGEMENT, LLC Other Pharmaceutical Preparations BUY $16.00 1,000,000 $16,000,000 3,138,412 +46.8%
2018-10-03 23:49 2018-10-01 UROV N/A Machado Patrick 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 00:50 2018-10-01 UROV N/A QVT Associates GP LLC 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 00:56 2018-10-01 UROV N/A VIKING GLOBAL INVESTORS LP 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-04 00:52 2018-10-01 UROV N/A VIKING GLOBAL PERFORMANCE LLC 10% owner Other BUY $14.00 2,678,571 $37,499,994 22,703,669 +13.4%
2018-10-03 04:35 2018-09-28 ETTX N/A ASTRAZENECA PLC 10% owner Other BUY $15.00 246,666 $3,699,990 2,164,855 +12.9%
2018-10-03 04:39 2018-09-28 ETTX N/A Pivotal bioVenture Partners Fund I, L.P. 10% owner Other BUY $15.00 337,724 $5,065,860 1,180,178 +40.1%
2018-10-03 04:40 2018-09-28 ETTX N/A Preston Heather Director, 10% owner Other BUY $15.00 337,724 $5,065,860 1,180,178 +40.1%
2018-10-03 00:20 2018-09-28 GRTS N/A Clarus Lifesciences III, L.P. 10% owner Other BUY $15.00 333,333 $4,999,995 333,333 +100.0%
2018-10-02 23:08 2018-09-27 SPKE Via Renewables, Inc. Maxwell W Keith III Director, 10% owner Electric & Other Services Combined BUY $8.20 123,904 $1,015,492 1,184,338 +11.7%
2018-10-02 17:01 2018-09-28 AIRT Air T, Inc. Swenson Nicholas John Director, Officer, 10% owner - CEO Air Courier Services BUY $33.55 30,000 $1,006,500 32,304 +1,302.1%
2018-10-03 00:23 2018-09-28 GRTS N/A Simon Nicholas Director, 10% owner Other BUY $15.00 333,333 $4,999,995 333,333 +100.0%
2018-10-02 21:31 2018-10-01 STRO SUTRO BIOPHARMA, INC. Merck & Co., Inc. 10% owner Biological Products, (No Diagnostic Substances) BUY $15.00 666,666 $9,999,990 2,723,509 +32.4%
2018-10-03 04:38 2018-09-28 ETTX N/A Frazier Life Sciences VIII, L.P. 10% owner Other BUY $15.00 375,887 $5,638,305 1,349,953 +38.6%
SHOW ENTRIES

Institutional Conviction in Form 4

Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.

Filtering the Market Noise

Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.